Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter.
Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.
Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.
OCR for page 32
THE GENOME:: NUTRITION AND HUMAN VARIATION
iA, `,o Motulsky
This paper presents an overview of the role of genetics
in nutrition and nutritional policy. It includes
discussions of human individuality and how it is
controlled by genetics, some examples of common and rarer
diseases in which genetics plays an important interactive
role, and some of the problems of-public policy raised by
our current knowledge of genetics and how these problems
will compound as our knowledge of genetics increases over
the next 10 to 20 years.
HUMAN lIARIABILITY
Human variability, or genetically controlled
variability, is very common. All people who are not
twins look different; clearly, this is genetically
controlled. We also tend to resemble our relatives more
than we do our nonrelatives, and these similarities in
physiognomy are controlled by genes. The similarity in
physiognomy is also carried over in the ways that people,
for example, hold their hands or~make gestures. Thus,
aspects of behavior that we do not ordinarily think of as
being under genetic control are, in fact, controlled by
genes. Although we do not know which genes are involved
in physical or behavioral resemblance, we do know that
genes are involved.
Over the past 20 years or so, internal genetic
variability has also become apparent. For example, blood
groups and various enzyme and protein types are now known
to be genetically determined. The HLA variants also show
tremendous genetic variability. More recently,
chromosomal variants have shown considerable variability
at the DNA level. Since most human DNA does not code for
protein, the variability of UNA is usually not expressed
32
OCR for page 32
phenotypically. However, such variability can be used,
and is being used increasingly, as a marker for genes
lying next to these DNA variants that are expressed.
What this research indicates is that if we take just a
few markers (but not DNA markers or HLA markers), we can
show that the chance that two randomly selected people
will have the sane genetic type becomes extremely small.
If we then add all known markers to the equations, we can
establish mathematically that all people, except, of
course, identical twins, are unique internally in respect
to their various genetic markers.
The question therefore arises: How important is this
variability in nutrition and health? To answer this, we
must consider the nature of internal variability. If we
assume that a gene is fully expressed and look at those
that carry the gene and those that don't (i.e.,
homozygotes), there are found to be two distinct
populations or distributions. If we assume that some
people are heterozygotes and if we can distinguish
between the two homozygotic and one heterozygotic
populations, then there will be three separate
distributions or curves. Since many genes interact with
a variety of other genes (the so-called polygenetic
situation), however, we most often get a single Gaussian
distribution curve that is very common for all kinds of
biological phenomena. This can be observed in the case of
a very simple genetic interaction of just two pairs of
additive genes. For example, the variability of enzyme
levels within the normal ranges often has a simple
genetic basis, because different alleles at a Gene locus
that specifies one structure or a given enzyme may be
associated with slightly different mean enzyme levels.
Thus, the widely variable quasi-Gaussian distribution of
activity for a given enzyme in a population may be the
result of few overlapping curves, each of which is
characteristic of its underlying allele.
. ~ . .. . . _
. ~
What is the relevance of this variability to nutrition?
As is well known, there are many intrinsic processes of
nutrition. These include absorption of nutrients, as
well as their distribution, catabolism, uptake by
receptors, transport across cells, storage, and
excretion. It would therefore be surprising if the high
degree of variability in the human biochemical makeup did
not affect these processes, thereby influencing
nutritional requirements and interactions.
33
OCR for page 32
Another point to consider is common variability.
Several hundred inborn errors of metabolism, in which a
variety of enzymes are absent or deficient, are known to
us; many of these are known to lead to gross
abnormalities in the organism. For example,
phenylketonuria (PKU), a relatively common condition
marked by the absence of the enzyme phenylalanine
hydroxylase, occurs in the homozygous state in about 1 of
12,000 to 1 of 15,000 people. This disease, which leads
to mental retardation if unchecked, can be prevented by
restricting phenylalanine in the diet. It takes a double
dose of the gene to produce PKU (as it does for most
inborn errors of metabolism), and that is why recessive
diseases such as PKU are relatively rare. From what we
know of genetic arithmetic (i.e., the Hardy Weinburg
Law), however, for every rare homozygote in the
population, there are many heterozygotes or carriers of
the gene. Thus, for an autosomal recessive disease like
PKU in which 1 in 12,000 people is affected, we can
estimate that approximately 2% of the population carry
the gene.
What, then, are the implications of this common carrier
state for nutrition and health? In general, people who
are affected with such inborn errors have very little to
no activity of the involved enzyme, while normal people
have about 100% activity and carriers have about 50%
activity. Under most conditions, a 50% level of enzyme
activity is sufficient for adequate function and carriers
remain in good health. Under conditions of growth,
stress, illness, or malnutrition, however, a 50% level of
enzyme activity may not be sufficient to maintain health,
and specific abnormalities related to the underlying
enzyme activity could result.
Familial hypercholesterolemia is an example of how a
heterozygotic or carrier state for a metabolic condition
can cause a relatively high disease rate. Another
example of variation that affects food likes and
dislikes, and, thus, probably nutritional status, is
phenylthiocarbamide (PTC) nontasting. PTC nontasting is
an example of a common monogenic trait that makes a
significant proportion of the affected population unable
to taste bitter substances. There are also less
well-studied examples, such as variability in the ability
to taste artificial sweeteners. Such subtle differences
undoubtedly affect food preferences.
34
OCR for page 32
Genes do not act in a vacuum, and the action of a
specific gene may depend not only on other genes but also
on the environment. This principle is well illustrated
by the field of pharmacogenetics. Certain inherited
enzyme variants are harmless per se but they may cause
untoward effects in the presence of a drug that requires
the normal variety of that enzyme for its inactivation.
In such cases, the presence of the enzyme variant by
itself without the drug or the administration of the drug
to people with the normal enzyme levels may cause no
harm. If the drug is given to carriers of the enzyme
variant, however, a drug reaction may ensue. Examples of
this phenomenon include hemolytic anemia from
glucose-6-phosphate dehydrogenase (G6-PD) deficiency,
prolonged apnea from pseudocholinesterase variation, and
various drug reactions associated with defective
acetylation of drugs such as isoniazid.
EXAMPLES OF THE INTERACTIVE ROLE OF GENETICS
The concept of pharmacogenetics can also be applied to
ecogenetics, that is, the interaction of specific genetic
traits with any environmental agent to produce a given
effect. Some ecogenetic examples of nutritional interest
include (1) the development of gastrointestinal symptoms
upon drinking moderate quantities of milk among the many
individuals with genetically determined lactose
intolerance; (2) the development of hemochromatosis in
susceptible individuals who consume moderate dietary
levels of iron; and (3) the development of hypertension
in genetically predisposed people who migrate from a less
developed, primitive environment to a more industrial
Westernized environment.
For example, lactose intolerance, a common trait in
which there is a persistence of the lactase enzyme in the
intestine, is an excellent example of a simple genetic
trait that affects absorption of commonly used foods,
namely, products containing lactose. At the time of
birth, all humans (as all other mammals) are able to make
and use the intestinal enzyme lactase to break down the
main constituent of milk, lactose, into glucose and
galactose. In most humans, the ability to digest lactose
disappears after weaning, but some individuals do not
lose this ability and have persistent intestinal lactase
activity (Lisker, 1984~. Symptoms in lactose
35
OCR for page 32
malabsorbers occur because undigested lactose in the
gastrointestinal tract is decomposed by bacteria, causing
bloating, diarrhea, intestinal rushes, flatulence, and
even nausea and vomiting in severe cases.
The lactose
persistence is controlled by a gene (L) that may occur in
the heterozygote (L1) or homozygote (LL) state. People
who do not carry the L gene, and who therefore cannot
digest lactose after weaning, are homozygotes (11) at
this locus, which is the usual status for most of the
world's population. Milk drinking does not induce
lactase activity in those who no longer have this
capacity, nor does lactose restriction reduce-the
intestinal lactase activity among those who never lost
it. Lactose absorption (L1 or LL) or malabsorption (ll)
is an inborn trait.
. .
Acute or chronic gastrointestinal
disease may cause secondary hypolactasia among
individuals with persistence of lactase activity, but
intestinal lactase activity returns after the illness.
Members of most populations have hypolactasia of the
genetic variety. Only people from central and northwest
Europe and from areas in Africa with a long history of
dairy activity have high frequencies of persistence of
lactase activity. Presumably, the gene for lactase
persistence had a survival advantage in cultures with
dairy activities, and over the generations it has
increased in frequency because individuals who were able
to absorb milk as children and young adults were either
more fertile or less likely to die.
Another example of how genetic variation influences
nutrition is the condition hemochromatosis. Those people
who are affected are homozygotes for a gene that
facilitates increased iron absorption and is carried on
the short arm of chromosome 6, which is closely linked to
the HLA-A locus. The homozygous state affects about 1 of
600 to 1 of 1,000 individuals in the United States and
Western Europe, indicating that about 10% of the
population is a heterozygote for or carrier of the
condition. Clinically apparent disease is more common
among males, since females can eliminate some excess iron
in their periodic menses. Since iron deficiency is
common among the population at large, supplementation of
flour with iron has been recommended by public health
authorities and is practiced in Sweden. The onset of
clinical hemochromatosis in homozygotes presumably would
be hastened by such a process. However, since the
proportion of people with the homozygous hemochromatosis
36
OCR for page 32
genotype is at most 1 in 500, some observers think that
the merits of iron supplementation benefit a much larger
fraction of the population and outweigh the damaging
effects of excess iron in homozygotes. A crucial issue
in this connection is related to the iron absorption
status of the very common hemochromatosis heterozygotes
(i.e., close to 1 in 10 people). However, current data
suggest that while liver iron stores are somewhat
increased among male heterozygotes as they get older,
there is no evidence that heterozygotes are at risk for
clinically apparent iron toxicity.
Another example of ecogenetics is that of high blood
pressure and salt. Hypertension is an ecogenetic trait
in that populations from less developed locales have
little or no hypertension. High blood pressure develops
in some migrants to a Western-type environment when the
diet includes a high salt intake. Populations of African
origin in the U.S. have a higher mean blood pressure and
a higher frequency of hypertension than those of European
origin. ~ ~ ^^ ~ ~~ ~
recently Discovered ul~terences between black
and white hypertensive populations include the absence of
elevated red blood cell sodium and lithium
countertransport in blacks--a finding that is also common
among white hypertensives. This transport trait appears
to be under monogenic control. This and other evidence
suggests that hypertension is a heterogenous entity with
different genetic mechanisms.
The fact that blood pressure levels are under strong
genetic control is shown by studies in families, adopted
children, and twins. Evidence for the role of sodium in
the causation and maintenance of high blood pressure is
also good. On a population level, the frequency of high
blood pressure in different populations is related to
their average sodium intake. However, sodium loading
does not cause elevation of blood pressure in all
individuals, and sodium restriction lowers blood pressure
in many, but not all, hypertensives. Salt restriction
has been advocated to reduce the frequency of high blood
pressure, but it may not be helpful for the entire
population. Currently, we lack clinical or laboratory
criteria to differentiate those individuals who are salt
resistant from those who are salt sensitive.
Another trait that is important for public health is
obesity. Obesity clearly is related to food intake,
37
OCR for page 32
although a variety of studies indicate that food intake
alone does not explain all the variation in obesity.
Studies done in twins have been useful in this regard.
Assuming that all human variation is genetic, we would
expect correlations between identical twins who share
100% of their genes to be 1.0, while we would expect it
to be 0.5 between unidentical twins, who share half of
their genes. In the case of body mass index, the
correlation for identical twins is 0.8, while that for
nonidentical twins is 0.42. This suggests that genetics
plays a major role in the risk of obesity. In addition,
studies have shown that children seem to have a body
weight that resembles that of their biological parents
more than that of their adoptive parents. This again
suggests that genetic factors are involved. The exact
mechanisms that make some people obese and others not are
not yet known.
Lastly, I would like to consider how genetics modulates
hyperlipidemia and coronary heart disease. Both genetic
and environmental factors influence a variety of
different lipid parameters that are involved in
hyperlipidemia and heart disease. Cholesterol levels in
serum as well as low high-density lipoprotein levels,
high apolipoprotein B levels, and low apolipoprotein Al
levels have all been implicated as risk factors for
coronary heart disease. Various alleles at the
apolipoprotein E locus have a significant effect on
raising or lowering cholesterol and apolipoprotein B
levels. Monogenic defects causing hypercholesterolemia
(i.e., familial hypercholesterolemia due to a low-density
lipoprotein receptor defect) have been carefully defined,
whereas the evidence for single-gene inheritance of some
other lipid abnormalities has been less certain but
suggestive. Regardless of the genes involved, genetic
factors of some sort play a role in most of the
hyperlipidemias. A common condition known as familial
combined hyperlipidemia appears to be transmitted as a
monogenic autosomal dominant trait and is usually
associated with elevation of apolipoprotein B levels.
Various DNA markers of the apolipoprotein loci have been
associated with hyperlipidemia and with coronary heart
disease but the results have not always been consistent.
Considerable research work is being carried out in these
areas and is likely to clarify the exact contribution of
genetic factors to hyperlipidemias.
38
OCR for page 32
PROBLEMS OF PUBI
POLICY __
GENETICS
What, then, are the nutrition policy implications of
genetic variability? Given the probable effects of
biological variability on nutritional requirements and
chronic disease, we should first ask whether different
dietary guidelines might be required for different
populations or individuals. If variability is small and
it can be overcome with general nutritional guidelines
that are easy and acceptable to everyone, then one can
ignore genetic variability-and make a single
recommendation for everyone. For example, we know that
there is genetic variability in caries susceptibility,
but fluoride is still given to everyone anyway.
The situation becomes less clear when we know that a
general guideline helps many but may hurt a few. The
fortification of foodstuffs with iron, increasing the
risk of hemochromatosis in susceptible heterozygotes, is
one such example. Another point bears on this issue of
individual versus population recommendations. Some argue
that a lowering of the cholesterol level of Western
populations by dietary modifications would substantially
reduce the frequency of coronary heart disease,
regardless of genetic variaticholesterol level from 226
to 210 mg/dl, as might be achieved with dietary
modification, would reduce the absolute risk of mortality
from coronary heart disease only slightly. However, a
small reduction in absolute risk for any individual may
have a major effect when it is translated into the very
large number of individuals that constitute the
population. This is the so-called prevention paradox
named by the British epidemiologist Geoffrey Rose. In a
hypothetical example, assume that a person can
reducetuation becomes less clear when we know that a
general guideline helps many but may hurt a few. The
fortification of foodstuffs with iron, increasing the
risk of hemochromatosis in susceptible heterozygotes, is
one such example. Another point bears on this issue of
individual versus population recommendations. Some argue
that a lowering of the cholesterol level of Western
populations by dietary modifications would substantially
reduce the frequency of coronary heart disease,
regardless of genetic variati the risk of having a
myocardial infarct in a given time span from l in 80 to 1
in 100 by altering his or her diet. If these figures
were applied to lOO,OOO individuals, the expected
39
OCR for page 32
i
frequency of 1,250 myocardial infarcts (1 in 80) would be
reduced to 1,000 heart attacks (1 in 100~. This
reduction of 250 heart attacks per 1,000 individuals at
risk would be of substantial public health importance
Although little is known about the effect of
nutrition-genetic interactions on lipids, however, it is
likely that some individuals are sensitive to dietary
lipids while others may be resistant. The roles of the
low-density lipoprotein receptor, structural variation in
apolipoproteins B and E, the regulation of hepatic
apolipoprotein B synthesis, and many other factors need
to be studied to resolve these issues.
Public health policies have largely ignored genetic
variation and have used an "average" human being in their
formulation. Thus, nutritional recommendations have
usually been set to provide a sufficient amount of a
nutrient even for those with the highest requirements.
With relatively small variation for a given nutrient,
such a nolicv annears sound.
Also, if special dietary
requirements affect a few individuals with inborn errors
of metabolism, policy recommendations can ignore such
outliers since these individuals can be identified and
will be treated by physicians. In many instances,
however, the true extent of genetic variation is still
unknown. We are indeed all different. We taste things
differently; we smell things differently and as noted
earlier, it is likely that these differences influence
the nutritional metabolic processes, requirements, and
interactions that can lead to chronic disease. Judging
from the frequency of genetic variants in enzymes and
proteins and their effects on enzyme activity,
significant variations in nutritional requirements or in
genetic-nutrition interactions may often exist.
Thus, while population-based guidelines may, for the
most part (at present), be sound, each nutritional topic
must be considered on its own merits. In addition, since
there are sizable racial or ethnic differences in disease
frequencies, it is conceivable that a recommendation for
one group of the population may need to differ from that
for the other groups. Such differences among races may
raise difficult policy questions because they can easily
be misunderstood. However, there are precedents from a
nonnutritional setting. Ashkenazi Jews are already
40
OCR for page 32
screened for Tay Sachs disease, Mediterraneans and
Southeast Asians are screened for thalassemia, and blacks
are screened for sickle cell disease and trait.
Under ideal circumstances, we could tailor dietary
recommendations to each individual, depending On his or
her genetic makeup or susceptibility. Although we have
an inkling of the extent and type of human variation,
however, much more work is needed to elucidate the
descriptive, metabolic, and biochemical bases of this
genetic variation. Sensible dietary recommendations can
be made for the general population, although we must not
ignore individual needs. What we must remember is that
the population approach and the individual approach are
complementary, not opposite, and that both are necessary
if we are to approach the resolution of the problems of
nutritional requirements and nutritional disease.
41